| Literature DB >> 33777099 |
Kurt D Christensen1,2,3, Megan Bell4, Carrie L B Zawatsky5,6, Lauren N Galbraith1, Robert C Green3,5,6,7, Allison M Hutchinson4, Leila Jamal8,9, Jessica L LeBlanc1, Jennifer R Leonhard10, Michelle Moore4, Lisa Mullineaux11, Natasha Petry12,13, Dylan M Platt4, Sherin Shaaban14,15, April Schultz4,16, Bethany D Tucker4, Joel Van Heukelom4,16, Elizabeth Wheeler4, Emilie S Zoltick1, Catherine Hajek4,16.
Abstract
Genetic testing has the potential to revolutionize primary care, but few health systems have developed the infrastructure to support precision population medicine applications or attempted to evaluate its impact on patient and provider outcomes. In 2018, Sanford Health, the nation's largest rural nonprofit health care system, began offering genetic testing to its primary care patients. To date, more than 11,000 patients have participated in the Sanford Chip Program, over 90% of whom have been identified with at least one informative pharmacogenomic variant, and about 1.5% of whom have been identified with a medically actionable predisposition for disease. This manuscript describes the rationale for offering the Sanford Chip, the programs and infrastructure implemented to support it, and evolving plans for research to evaluate its real-world impact.Entities:
Keywords: decision support systems – clinical; genetic counseling; genetic testing; pharmacogenomic testing; primary health care
Year: 2021 PMID: 33777099 PMCID: PMC7994529 DOI: 10.3389/fgene.2021.626845
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599